Strategic partnerships DiaCarta collaborates with Capstone Health Alliance and OncoAssure to expand access to precision diagnostics and prostate cancer tests, indicating strong growth opportunities through GPO channels and co-developed offerings in oncology.

Prostate cancer tools Recent partnerships focus on prostate cancer diagnostics to identify low recurrence risk and guide active surveillance, presenting a sales path for targeted molecular tests and monitoring solutions in urology and oncology support services.

Liquid biopsy focus DiaCarta emphasizes ultra-sensitive liquid biopsy technologies for cancer and infectious diseases, suggesting upsell opportunities for clinicians and labs adopting non-invasive diagnostic workflows and prognostic monitoring.

OTC and at-home expansion Launch of at-home Fecal Occult Blood Test products signals interest in consumer-facing diagnostics, opening cross-sell potential to retailers, direct-to-consumer channels, and integration with physician-supported care pathways.

Global collaboration Strategic collaborations across the US and Europe (Ireland, California) indicate readiness to scale through international partnerships, licensing or distribution deals, and multi-market clinical adoption of DiaCarta’s tests.